Groundbreaking medical technology with a Swedish heritage
Non-invasive measurement of gases
The innovative technology in Neola® that allows for continuous monitoring and surveillance of preterm born infants’ lungs is called GASMAS (gas in scattering media absorption spectroscopy) – a groundbreaking method for measuring gases in body cavities that has been patented by Neola Medical. GASMAS was originally developed by researchers at Division of Atomic Physics at Lund University and has been further refined by Neola Medical.
GASMAS technology in Neola® that allows for non-invasive continuous lung monitoring of preterm born babies
GASMAS’ biomedical application currently enables non-invasive measurement of lung volume changes and oxygen gas concentration directly in the lungs. This method is completely revolutionary and unique and is based on the specific light absorption by oxygen and water vapor gas molecules compared to the absorption by liquid and solid compounds of tissue.
GASMAS is currently being applied in Neola®, a medical device that can monitor the lungs of preterm born infants. A clinically proven and commercialized GASMAS technology has potential to fill even more gaps in health care by offering a safe and non-invasive method to measure volume changes and composition of gases inside cavities of the body.
Professor Katarina Svanberg and Professor Sune Svanberg
The technology founders
The technology founders include Professor Sune Svanberg, a distinguished physicist who served on the Nobel Prize election committee for many years, alongside his wife, Professor Katarina Svanberg, a renowned medical doctor.
The gas measurement technology is based on years of research at Lund University. The first lung measurements using the GASMAS technology were conducted as part of a research project and were published in 2011 by Neola Medical’s Chairman of the Board, Märta Lewander Xu, during her doctoral studies under the supervision of Professor Sune Svanberg and with Professor Katarina Svanberg as co-supervisor.
Keynote lecture on GASMAS technology by esteemed U.S. Professor in Neonatology
Neola Medical is proud to have had the opportunity to participate and showcase its GASMAS technology in the Xth RECENT ADVANCES IN NEONATAL MEDICINE Congress, held from October 12-14, 2024, in Würzburg, Germany. This prestigious event brought together over 500 of the world’s leading neonatal care experts, providing an invaluable platform for knowledge exchange and progress in the MedTech field.
At the Congress, Neola Medical was honored to sponsor a highly anticipated keynote lecture by esteemed U.S. Professor Vineet Bhandari, Division Head of Neonatology at The Children’s Regional Hospital at Cooper, Camden, USA. His presentation, titled “GASMAS Transit to the NICU – Are We There Yet?”, provided valuable insights into the potential of GASMAS technology to enhance clinical outcomes for preterm born infants.
“Technology innovation that may improve the clinical outcome of preterm born babies is of highest interest to neonatologists around the world. GASMAS appears to be safe, and if shown to be accurate and reliable, it may improve our knowledge of alveolar oxygen concentration and content and its changes during postnatal transition and in diverse neonatal lung conditions, including respiratory distress syndrome, BPD, pneumothorax, pneumonia, atelectasis, and pulmonary edema, among others. Future clinical studies can then determine the cost effectiveness and utility of GASMAS in improving neonatal outcomes. The potential of GASMAS technology in modern neonatal care is an exciting step forward in neonatal medicine, and I look forward to sharing its potential future with healthcare professionals from around the world.”
– Professor Vineet Bhandari
CEO Hanna Sjöström and MD DM Professor Vineet Bhandari, Division Head of Neonatology at The Children’s Regional Hospital at Cooper, Camden, USA.
Three-Part Video Series on Professor Bhandari’s Keynote Lecture
“GASMAS Transit to the NICU – Are We There Yet?”
Each segment offers valuable insights into how GASMAS technology could improve neonatal care and clinical outcomes for preterm born infants. Watch the full series to explore the key takeaways and expert perspectives.
For Investors
We are on a journey to revolutionize neonatal intensive care
Learn more about investing in Neola Medical